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Abstract From a neuropathological perspective, elderly
patients who die with a clinical diagnosis of sporadic
Alzheimer’s disease (AD) are a heterogeneous group with
several different pathologies contributing to the AD phe-
notype. This poses a challenge when searching for low
effect size susceptibility genes for AD. Further, control
groups may be contaminated by significant numbers of
preclinical AD patients, which also reduces the power of
genetic association studies. Here, we discuss how cere-
brospinal fluid and imaging biomarkers can be used to
increase the chance of finding novel susceptibility genes
and as a means to study the functional consequences of risk
alleles.
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Introduction
Alzheimer’s disease (AD) is considered the most common
form of dementia, but still lacks effective preventive or
therapeutic interventions. This is probably partially due to
an incomplete understanding of AD aetiology and the
possible confounding factors associated with its genotypic
and phenotypic heterogeneity. The disease was named after
Alois Alzheimer, who in the early 20th century described
cases of ‘‘presenile dementia’’, with neuropathological
features characterized by gross cerebral atrophy, extracel-
lular senile plaques and intracellular neurofibrillary tangles.
Although there were some early doubts about the distinc-
tion between early-onset and late-onset dementia, during
the first half of the 20th century, AD was mainly thought of
as a rare disease that affected middle-aged people, while
most elderly people with dementia were considered to have
‘‘senile dementia’’, caused primarily by age-related vas-
cular pathology [1]. AD was only recognized as an
important cause of dementia in elderly people after several
autopsy studies in the 1950s to 1970s had noted the high
prevalence of AD-like neuropathology in patients with
‘‘senile dementia’’ [2, 3].
During the 1980s to 1990s, breakthroughs in biochem-
istry and genetics laid the basis for strong hypotheses about
the cause of AD, which first led to the development of the
symptomatic treatments that are currently available [4],
and second to clinical trials of therapeutic approaches
targeted against amyloid b (Ab), the major component of
senile plaques and a potential driver of the disease [5, 6].
Several lines of data point to significant pathological and
clinical heterogeneity among clinically diagnosed AD
patients. Many autopsy studies have shown that most
elderly patients with dementia have mixed pathologies,
with AD-like pathology combined with other brain
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pathologies, such as Lewy bodies, white matter disease,
angiopathy, or TDP-43 inclusions [7–10]. After AD, the
most common dementia form is dementia with Lewy
bodies (DLB), characterized by the accumulation of
a-synuclein aggregates and cognitive impairment that is
not dominated by memory decline, but rather executive and
visuospatial problems, and a high frequency of hallucina-
tions and delusions. About 10–40 % of AD patients have
concomitant Lewy bodies [11–13], which likely affects the
clinical course of AD, since AD patients with Lewy bodies
have faster cognitive decline than those without Lewy
bodies [14]. So far, it remains very difficult to identify
Lewy body pathology in AD patients in vivo. Another very
common cause of dementia is cerebrovascular disease.
Vascular cognitive impairment defines alterations in cog-
nition, ranging from subtle deficits to full-blown dementia,
attributable to cerebrovascular causes. Often coexisting
with AD, mixed vascular and neurodegenerative dementia
has actually been proposed as the leading cause of age-
related cognitive impairment and dementia [15]. Bio-
marker changes that associate with cerebrovascular dis-
ease, e.g., white matter changes on computed tomography
or magnetic resonance imaging (MRI) of the brain and
elevated CSF levels of neurofilament light, are common in
elderly patients with clinical AD [16], and it is possible that
the dementia syndrome in some of these individuals is not
driven by AD pathology but rather deficits in the cere-
brovasculature. Susceptibility genes for AD pathology will
not be found in these patients.
Here, we share our view on what could be gained by
performing genetic studies on patients with more extensive
information on underlying pathologies using different
forms of biomarkers. The focus is on AD-related patholo-
gies but the reasoning should be relevant also to other
neurodegenerative diseases.
Biomarkers for AD Pathology
During the last two decades, biomarker tools have been
developed, which allow researchers and clinicians to
identify AD-like pathology in vivo, even years before the
first symptoms emerge. Cerebrospinal fluid (CSF) levels of
total tau and phospho-tau are positively correlated to neu-
rodegeneration and neurofibrillary tangle pathology,
whereas CSF levels of aggregation-prone 42 amino acid
long Ab (Ab42) are negatively correlated to plaque
pathology [17]. A recent meta-analysis assessing studies in
which clinical criteria were used suggests that the combi-
nation of CSF tau and Ab markers shows a sensitivity of
84 % (76–90 %) and a specificity of 71 % (59–81 %) for
AD both in dementia and mild cognitive impairment stages
of the disease [18]. Further, plaque pathology can be
visualized using amyloid positron emission tomography
(PET) [19], and tau PET is a more recent potential bio-
marker tool to monitor tangle pathology [20]. The first
biomarker changes indicating Ab build-up in the brain
appear 10–20 years before clinical onset of the disease
with Ab markers preceding tau markers by 5–10 years [21,
22•]. This puts Ab before tau in regards to the sequence of
events during the disease process. However, much remains
to be learnt regarding what factors may initiate Ab
deposition.
Genetics of Sporadic AD
APP and PSEN Mutations
The causative roles of mutations in the amyloid b precur-
sor protein (APP) and presenilin (PSEN1 and PSEN2;
encoding the active site of c-secretase that produces
Ab from APP with most mutations resulting in qualitative
changes in APP-processing which promote cerebral
b-amyloidosis [23]) genes in familial AD have long been
recognized [24]. However, genetic analysis of late-onset
sporadic AD has surprisingly revealed that these mutations
are also pathogenic in some cases of late-onset AD and
CSF biomarkers have been used as endophenotypes to
detect mutations in the genes known to harbour AD-caus-
ative mutations [25, 26]. The Swedish APP mutation cau-
ses AD because it makes the protein a better substrate for
BACE1 (the major b-secretase responsible for cleaving
APP in the N-terminal part of the Ab domain making the
remaining stub a c-secretase substrate) and thus more APP
is metabolized along the amyloidogenic pathway and more
Ab is produced [27]. In a recent study, Jonsson and col-
leagues [28•] noted that a specific mutation in APP, which
previously had been identified to be located close to the
b-secretase site [29], made it a worse substrate for BACE1
and correspondingly was associated with lower Ab pro-
duction and lower risk of AD. This observation, if repli-
cated, supports the Ab cascade hypothesis and also BACE1
inhibition as a valid target for AD therapy. Autosomal
dominant mutations that cause familial AD without effect
on Ab metabolism have not yet been reported. The study of
AD biomarkers in these familial cases has been essential to
establish the timeline of pathological events in the disease,
and in particular, to support the existence of a long pre-
clinical stage [22•, 30].
A recent multicenter, longitudinal study of CSF in
families with autosomal dominant AD mutations revealed a
clear transition of CSF markers over-time with reduced
concentrations of CSF Ab1-42 (associated with the pre-
sence of amyloid plaques) and elevated concentrations of
CSF markers of neurofibrillary tangles and neuronal injury/
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death in asymptomatic mutation carriers 10–20 years
before their estimated age at symptom onset. The longi-
tudinal assessment also revealed an over-time decrease in
the concentration of injury-related markers after symptom
onset, suggesting a slowing of acute neurodegenerative
processes with symptomatic disease progression [22•].
APOE
The association of the apolipoprotein E (APOE) e4 allele
with AD is strong (odds ratios ranging from 3 to 10 in
different studies [31•]) and undisputed. ApoE is the major
carrier of cholesterol in the CNS and has also important
roles in Ab metabolism, aggregation, and deposition.
Increased plaque deposition has been observed in APOE
e4-positive individuals and in APOE e4 knock-in animal
models of cerebral b-amyloidosis [32–34]. ApoE binds Ab
but the apoE4 isoform has a lower affinity than apoE3, and
it appears that at least part of the association of APOE e4
with Ab plaque pathology is related to apoE4 being less
efficient in clearing Ab from the brain parenchyma [35].
This may explain why cognitively healthy people with
APOE e4 have biomarker signs of Ab pathology at an
earlier age than people lacking the APOE e4 allele (espe-
cially compared to people carrying the APOE e2 allele)
[36].
In a genome-wide study, the APOE e4 genotype was the
strongest single-genetic factor associated with CSF ApoE
protein levels. ApoE CSF, but not plasma, levels were
found to significantly associate with CSF Ab42 levels
independently of the APOE e4 genotype, and suggesting
that ApoE levels in CSF may be a useful endophenotype
for AD [37]. However, in contrast, APOE e4 does not
interact with age to produce biomarker signs of axonal
degeneration (increased CSF T-tau) or tangle pathology
(increased CSF P-tau), supporting the view that APOE e4
does not have a primary effect on these aspects of AD
pathology (alternatively, these biomarkers may have too
low sensitivity to identify such effects).
One study [38] has shown an interesting interaction
effect between APOE and Ab1-42 in the CSF of APOE e4
carriers. Homo- and heterozygotes of the APOE e4 allele
had significantly lower detectable Ab42 concentrations
than APOE e3 homozygotes. Although the exact mecha-
nism is not understood, the implication is for matrix
composition of these (and potentially other) proteins in
CSF to impact the measurement of corner-stone biomark-
ers such as Ab42, and perhaps aid exploration of patho-
relevant physiological processes. As such there may be
considerable utility for genetic and proteomic character-
isation of AD patients and research subjects.
Exactly how the ApoE4 isoform promotes AD is still
unclear, and conflicting results present in the literature
support both a loss of positive or gain of negative functions
of the protein. The role of ApoE in AD becomes even more
complex when considering the recent report of a patient with
a rare form of severe dysbetalipoproteinemia who was
homozygous for an ablative APOE frameshift mutation. As
expected, the patient had exceptionally high cholesterol
content with profound lipoprotein metabolism dysregulation.
However, this 40-year-old patient presented surprisingly
normal neurological-related features (normal vision, normal
cognitive, neurological, and retinal functions, normal find-
ings on brain magnetic resonance imaging, and normal CSF
levels of Ab and tau proteins) [39]. It would have been very
interesting to determine the CSF lipidation profile of this
patient, especially to assess the possibility of compensation
by other apolipoproteins, and further follow-up will reveal if
age-related neurological deficits will appear.
Other Susceptibility Genes
Genome-wide association studies (GWAS) identify com-
mon loci (typically frequencies of 10–50 %), which have
low to modest effects on risk (typically with odds ratios in
the 1.1–2.0 range). Over the last 5 years, this approach has
begun to yield large numbers of risk loci, and this harvest
continues as study pooling is ongoing and as larger num-
bers of samples are collected [40••]. The utility of these
studies in terms of predicting who will develop disease is
currently modest. However, their larger importance is that
they may identify pathways and processes in which genetic
variability affects disease risk. So far, GWAS have iden-
tified 3 such pathways: (i) endosomal vesicle recycling
(BIN1, PICALM and SORL1), (ii) the innate immune sys-
tem (TREM2, CR1 and CLU) and (iii) genes related to
cholesterol metabolism (ABCA7, CLU) [41]. It is not yet
possible to definitively relate these pathways directly to
each other or to Ab but they resonate well with recent CSF
biomarker data showing links between Ab pathology and/
or AD and CSF levels of endosomal/lysosomal network
proteins, and proteins related to microglial activation and
synaptic function or integrity [42–45].
Can Biomarkers Help us Finding More Risk Genes
for Sporadic AD?
There has been a recent surge in interest in the use of
endophenotypes in research on psychiatric and neurode-
generative diseases, AD in particular. The concept was
introduced by Gottesman and Shields to reduce the harmful
influence of poor accuracy in the clinical diagnosis of
psychiatric and neurological diseases on the power of
genetic association studies [46], which is a major problem
in AD research. In addition, the identification of disease
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endophenotypes offers the prospect of creating experi-
mental models relevant to human pathophysiology, which
will be suitable for experimental approaches and greatly
facilitate the development and screening of novel thera-
peutics. Endophenotypes may be described as internal
phenotypes that lie on the pathway between genes and
disease. Fundamental to the concept is the assumption that
variation in an endophenotype will depend upon variation
in fewer genes than the more complex disease phenotype
and therefore be more tractable to genetic analysis [46].
The combination of clinical and biomarker information (as
opposed to definition based on clinical data only) to define
cases and controls in genetic association studies increases
the power of these analyses. This could be inferred when
APOE e4 was found to present a stronger association with
AD when clinical criteria incorporated biomarker infor-
mation, and when genetic associations were replicated
using much smaller sample sizes when compared to the
original associations, by means of defining cases and
controls according to CSF biomarker profiles [31•].
In AD, CSF and imaging biomarkers have been used as
endophenotypes in several genetic studies, both to increase
the chance of finding novel susceptibility genes and as a
means to study the functional consequences of risk alleles.
These studies have been closely tied with genetic tech-
nology developments, moving from analyses of individual
genetic variants or genes to genome-wide approaches
(Fig. 1).
When studying specific variants/genes, these were
usually chosen given an a priori biological or aetiological
association with disease. This was the case when
Kauwe et al. identified a gene-physiological environment
interaction between MAPT common single-nucleotide
polymorphisms (SNPs) and Ab deposition through the
evaluation of the role of these SNPs in CSF tau/ptau levels
[50]. An analogous approach was used to study genes
involved in the complement system. Daborg et al. chose to
study the complement system because of its involvement in
both physiological and AD synapse elimination. The
authors studied 4 SNPs in different genes (C2, C3, CFB
and CR1) and although no significant associations were
found with AD risk, potential associations between SNPs
in C2 and CFB were identified in relation to CSF tau levels
and Mini-Mental State Examination (MMSE) scores [51].
Cruchaga and colleagues studied 384 SNPs selected
from genes known to code for the most relevant tau kina-
ses, phosphatases, and in other genes implicated in other
posttranslational modifications of tau, or tau degradation.
The authors were able to detect a SNP (rs1868402) in
PPP3R1 associated with CSF P-tau181 levels. This variant
showed a strong association with the rate of decline in AD
patients, but no association was detected with AD risk or
age at onset of the disease [49]. By taking a genome-wide
approach, the same group was able to identify 4 genome-
wide significant signals associated with CSF tau levels
(including tau and ptau): APOE; rs9877502 located at 3q28
between GEMC1 and OSTN; rs514716 located at 9p24.2
within GLIS3; and rs6922617 at 6p21.1 within the TREM
gene cluster [52•]. A clear signal that this is a valid
approach to identify novel risk variants for a complex
disease like Alzheimer’s is the fact that 3 (APOE, 3q28 and
6p21.1) of the 4 genome-wide significant loci identified
had also been independently associated with the disease
[53, 54, 55••, 56••].
To expand the use of endophenotypes beyond CSF
Ab42 and tau, Kauwe et al. studied the CSF levels of 59
Fig. 1 Evolution of genetic studies based on endophenotype associations in Alzheimer’s disease. Examples of studies [47, 48•, 49]
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AD-related proteins in a GWAS study [48•]. They identi-
fied significant genetic associations with CSF levels of 5
proteins involved in amyloid processing and pro-inflam-
matory signalling: Angiotensin-converting enzyme (ACE),
Chemokine (C–C motif) ligand 2 (CCL2), Chemokine
(C–C motif) ligand 4 (CCL4), Interleukin 6 receptor
(IL6R) and Matrix metalloproteinase-3 (MMP3), suggest-
ing mechanisms for genetic control of CSF and plasma
levels of these disease-related proteins. Interestingly, the
SNPs found to be significantly associated in ACE and
MMP3 also showed association with AD risk [48•].
Can Biomarkers Help us to Characterize the Functional
Mechanisms of each Associated Loci in AD?
One of the limitations of case–control GWAS is the fact
that generally only haplotype tagging markers are identi-
fied by this methodology. When comparing frequencies of
genotypes between large numbers of cases and controls, it
would be very difficult to do this for every single variant in
the genome. To overcome this, GWAS platforms are based
on haplotypes and only SNPs tagging each haplotype are
analysed. Although this approach eases the burden of
comparative testing, it also prevents the identification of
specific disease-associated variants, as these can be in
linkage disequilibrium (LD) with the genome-wide hit
identified. An essential follow-up step to the identification
of GWAS significant loci for a disease is the character-
ization of the functional mechanisms by which the asso-
ciated variants influence the risk for disease. Kauwe et al.
used an endophenotype-based approach to attempt to
generate biological hypotheses of risk mechanism for
BIN1, CLU, CR1 and PICALM. To accomplish this, the
authors sampled common variation in these genes, geno-
typing 355 variants in over 600 individuals for whom
measurements of CSF Ab42 and P-tau181 had been
obtained. Although this was a well-designed study, no
associations between SNPs in these genes and CSF Ab42
or P-tau181 levels were found in the studied sample, sug-
gesting that the associated variants at these loci do not
affect risk via a mechanism resulting in a strong additive
effect on CSF levels of Ab42 or P-tau181 [57]. In a study
using family-based and case–control designs, Schjeide
et al. performed an analogous analysis of 5 variants in
CLU, CR1 and PICALM. The authors identified a signifi-
cant effect of rs541458 in PICALM on CSF Ab42 levels
[58]. With the same goal, Elias-Sonnenschein et al. studied
36 SNPs in 25AD-related genes in a cohort of 222 Finish
AD patients for which CSF biomarker levels were avail-
able. They identified several significant associations:
APOE e4, CLU rs11136000, and MS4A4A rs2304933 cor-
related with significantly decreased CSF Ab42; at an
uncorrected level PPP3R1 rs1868402 and MAPT
rs2435211 were related with increased T-tau; SORL1
rs73595277 and MAPT rs16940758 were associated with
increased P-tau [59].
Altogether, these studies clearly point to the need of
structured, well-powered analyses. The application of this
approach to other loci, the increase in the number of samples
studied and the use of replication cohorts will probably allow
for a deeper characterization of these associations.
Conclusions
The integration of genetic results with biomarkers is
essential for advancing the research into AD and other
complex disorders. Genetic studies clearly have an extreme
potential for the identification of novel biomarkers for AD,
but biomarkers are also essential for the guiding of genetic
studies both in familial and sporadic forms of the disease.
The use of endophenotypes in GWAS adds a layer of
information to this type of study because it directly asso-
ciates with specific disease-related biological mechanisms.
The computational ability to test for associations in well-
structured studies at a genome-proteome-wide level will
most likely reveal novel molecular interactions important
for the risk and progression of AD.
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